EGFR and non-small cell lung carcinoma: Patients with EGFR mutations in exons 19 and 21 have been shown to have significantly higher response rates and improved PFS when treated with frontline gefitinib, and EGFR mutation has become an established criterion for selecting an EGFR TKI as first-line therapy in stage IV NSCLC patients.